Episode #23: trazodone (Desryel) | Podcast Show Notes
trazodone (TRAZ oh done)
Below will be links for the full Podcast and the Drug Card for trazodone along with a brief summary of various points on trazodone.
QUESTIONS:
- Select all that apply.
- A). Major Depressive Disorder is an off label indication for trazodone
- B). Major Depressive Disorder is an approved indication for Desryel
- C). Insomnia is an off label indication for Desyel
- D). Trazodone is approved only for insomnia in children but not MDD
- What is the typical dose range for MDD?
- What is the Black Box Warning for trazodone for?
- T or F: Trazodone may increase bleed and bruise risk for patients.
SUMMARY:
Trazodone is an antidepressant that also is commonly used for insomnia (off-label). When treating MDD in adults the immediate release tablet is initiated at 50 mg twice daily and incrementally increased every 3-7 days to a typical dose range between 200-400 mg/day. If used for treating MDD and if the sedative effect is not desired it is recommended to have a smaller daytime dose and a larger bedtime dose. When treating insomnia dosing is initiated at 50-100 mg at bedtime. Most common side effects are sedation, dizziness, and low blood pressure. Serotonin syndrome is a concern so watch for symptoms such as agitation, hallucinations, coordination problems, fast heartbeat, sweating, fever, n/v/d, and tight muscles. Trazodone has a Black Box Warning for Suicidal Thoughts and Behaviors so patients should be monitored for clinical worsening and the emergence of suicidal thoughts and behaviors.
ANSWERS:
- B and C are correct. “A” incorrect because MDD is not an off label use. “D” is incorrect because trazodone is approved for use in children.
- 200-400 mg/day (split into two doses).
- Suicidal Thoughts and Behaviors.
- True. Medications that affect serotonin have been associated with an increase in bleed and bruise risk.
PDF of Drug Card: trazodone
